SMN1 and spinal muscular atrophy, type 1: This gene-replacement strategy has been clinically successful, leading to the first licensed virally mediated gene replacement for a severe neurological disease, spinal muscular atrophy type 1 (SMA1), which is caused by loss of SMN1 in spinal motoneurons (1).